gip glp 1 agonist tirzepatide GLP-1/GIP dual alleviates mice model of Parkinson's disease by promoting mitochondrial homeostasis Tirzepatide: A Novel, Once-weekly Dual

Consult your doctor if you have hypothyroidism, kidney condition, or take blood thinners

Phase 2 data demonstrated: Up to 86% relative reduction in liver fat content Over 85% of participants on higher doses achieved resolution of hepatic steatosis More than 90% of participants with obesity and NAFLD achieved liver fat normalisation at top dose These findings suggest glucagon receptor agonism may play a pivotal role in lipid oxidation and hepatic fat mobilisation an area of intense scientific interest in UK metabolic research

For any questions about your dosage, please reach out through the Alan Health portal

Reconstitute only one vial at a time as needed

Hinson JA, Mays JB, Cameron AM

This advanced formula helps curb cravings, reduce appetite, and support healthy metabolism, all without stimulants or synthetic additives